Another alternative approach for SMA involves gene supplementation therapy, delivering a fully functional copy of the SMN1 gene using self-complementary adeno-associated viral (AAV) vectors, commonly packaged with serotype 9 (scAAV9). This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.